学科主题临床医学
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naive Patients Infected with Genotype 1b Hepatitis C Virus
Wang, Ye; Rao, Hui-Ying; Xie, Xing-Wang; Wei, Lai
关键词Antiviral Resistance Direct Antiviral Agents Hepatitis C Virus
刊名CHINESE MEDICAL JOURNAL
2015-10-05
DOI10.4103/0366-6999.166038
128期:19页:2625-2631
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]NS3 PROTEASE INHIBITORS ; FIXED-DOSE COMBINATION ; INTERFERON-ALPHA 2A ; PEGYLATED INTERFERON ; PLUS RIBAVIRIN ; NS5A INHIBITOR ; OPEN-LABEL ; VIROLOGICAL ESCAPE ; DRUG-RESISTANCE ; PHASE-2 TRIAL
英文摘要

Background: It has been reported that several baseline polymorphisms of direct-acting antivirals (DAAs) agents resistance-associated variants (RAVs) would affect the treatment outcomes of patients chronically infected with hepatitis C virus (CHC). The aim of this study is to investigate the prevalence of DAAs RAVs in treatment-naive GT1b CHC patients.

Methods: Direct sequencing and ultra-deep sequencing of the HCV NS3, NS5A, and NS5B gene were performed in baseline serum samples of treatment-naive patients infected with genotype 1b hepatitis C virus (HCVs).

Results: One hundred and sixty CHC patients were studied. Complete sequence information was obtained for 145 patients (NS3), 148 patients (NS5A), and 137 patients (NS5B). Treatment-failure associated variants of DAAs were detected: 56.6% (82/145) of the patients presented S122G for simeprevir (NS3 protease inhibitor); 10.1% (14/148) of the patients presented Y93H for daclatasvir and ledipasvir (NS5A protein inhibitors); 94.2% (129/137) of the patients presented C316N for sofosbuvir (NS5B polymerase inhibitor). Nearly, all of the DAAs RAVs detected by ultra-deep sequencing could be detected by direct sequencing.

Conclusions: The majority of genotype 1b CHC patients in China present a virus population carrying HCV DAAs RAVs. Pretreatment sequencing of HCV genome might need to be performed when patients infected with GT1b HCV receiving DAAs-containing regimens in China. Population sequencing would be quite quantified for the work.

语种英语
WOS记录号WOS:000362853100012
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64738
专题北京大学第二临床医学院_北京大学肝病研究所
作者单位Peking Univ, Peoples Hosp, Inst Hepatol, Beijing Key Lab Hepatitis & Immunotherapy Liver D, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Wang, Ye,Rao, Hui-Ying,Xie, Xing-Wang,et al. Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naive Patients Infected with Genotype 1b Hepatitis C Virus[J]. CHINESE MEDICAL JOURNAL,2015,128(19):2625-2631.
APA Wang, Ye,Rao, Hui-Ying,Xie, Xing-Wang,&Wei, Lai.(2015).Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naive Patients Infected with Genotype 1b Hepatitis C Virus.CHINESE MEDICAL JOURNAL,128(19),2625-2631.
MLA Wang, Ye,et al."Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naive Patients Infected with Genotype 1b Hepatitis C Virus".CHINESE MEDICAL JOURNAL 128.19(2015):2625-2631.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Ye]的文章
[Rao, Hui-Ying]的文章
[Xie, Xing-Wang]的文章
百度学术
百度学术中相似的文章
[Wang, Ye]的文章
[Rao, Hui-Ying]的文章
[Xie, Xing-Wang]的文章
必应学术
必应学术中相似的文章
[Wang, Ye]的文章
[Rao, Hui-Ying]的文章
[Xie, Xing-Wang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。